

1 **Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a**
2 **COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi**

3
4 Upendo L. Mseka^{1,2†}, Jonathan Mandolo^{1†}, Kenneth Nyoni^{2†}, Oscar Divala², Dzinkambani Kambalame²,
5 Daniel Mapemba², Moses Kamzati², Innocent Chibwe², Marc Y. R. Henrion^{1,3}, Kingsley Manda⁴, Deus
6 Thindwa¹, Memory Mvula¹, Bright Odala², Raphael Kamng'ona¹, Nelson Dzinza⁴, Khuzwayo C. Jere^{1,5,10},
7 Nicholas Feasey^{1,3}, Antonia Ho⁶, Abena S. Amoah^{7,8}, Melita Gordon^{1,5}, Todd D Swarthout⁹, Amelia
8 Crampin^{6,7,8}, Robert S. Heyderman⁹, Matthew Kagoli², Evelyn Chitsa-Banda², Collins Mitambo², John
9 Phuka¹⁰, Benson Chilima², Watipaso Kasambara², Kondwani C. Jambo^{1,3,10*}, Annie Chauma-Mwale^{2*}

- 10
11 1. Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi
12 2. Public Health Institute of Malawi, Lilongwe, Malawi
13 3. Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
14 4. National Statistical Office, Zomba, Malawi
15 5. Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United
16 Kingdom
17 6. University of Glasgow, Glasgow, United Kingdom
18 7. London School of Hygiene and Tropical Medicine, London, United Kingdom
19 8. Malawi Epidemiology and Intervention Unit, Lilongwe, Malawi
20 9. NIHR Mucosal Pathogens Research Unit, Research Department of Infection, Division of Infection and
21 Immunity, University College London, London, United Kingdom
22 10. Kamuzu University of Health Sciences (formerly University of Malawi, College of Medicine) Blantyre,
23 Malawi

24
25
26 ***Corresponding and joint senior authors**

27 Email: kjambo@mlw.mw (KCJ) or chaumaannie@gmail.com (AM)

28 † Contributed equally to this manuscript

29
30 **Main text:** 3311 words

31 **Running title:** Omicron-associated severe disease is rare in high seroprevalence settings in Malawi

32 Abstract

33 **Background.** The B.1.1.529 (Omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-
34 CoV-2) has resulted in the fourth COVID-19 pandemic wave across the southern African region, including
35 Malawi. The seroprevalence of SARS-CoV-2 antibodies and their association with epidemiological trends
36 of hospitalisations and deaths are needed to aid locally relevant public health policy decisions.

37 **Methods.** We conducted a population-based serosurvey from December 27, 2021 to January 17, 2022,
38 in 7 districts across Malawi to determine the seroprevalence of SARS-CoV-2 antibodies. Primary
39 sampling units (PSU) were selected using probability proportionate to the number of households based
40 on the 2018 national census, followed by second-stage sampling units that were selected from listed
41 households. A random systematic sample of households was selected from each PSU within the 7
42 districts. Serum samples were tested for antibodies against SARS-CoV-2 receptor binding domain using
43 WANTAI SARS-CoV-2 Receptor Binding Domain total antibody commercial enzyme-linked
44 immunosorbent assay (ELISA). We also evaluated COVID-19 epidemiologic trends in Malawi, including
45 cases, hospitalizations and deaths from April 1, 2021 through April 30, 2022, collected using the routine
46 national COVID-19 reporting system.

47 **Results.** Serum samples were analysed from 4619 participants (57% female; 65% aged 14 to 50 years), of
48 whom 1018 (22%) had received a COVID-19 vaccine. The overall assay-adjusted seroprevalence was
49 86.3% (95% confidence interval (CI), 85.1% to 87.5%). Seroprevalence was lowest among children <13
50 years of age (66%) and highest among adults 18 to 50 years of age (82%). Seroprevalence was higher
51 among vaccinated compared to unvaccinated participants (96% vs. 77%; risk ratio, 6.65; 95% CI, 4.16 to
52 11.40). Urban residents were more likely to test seropositive than those living in rural settings (91% vs.
53 78%; risk ratio, 2.81; 95% CI, 2.20 to 3.62). National COVID-19 data showed that at least a two-fold
54 reduction in the proportion of hospitalisations and deaths among the reported cases in the fourth wave
55 compared to the third wave (hospitalization, 10.7% (95% CI, 10.2 to 11.3) vs 4.86% (95% CI, 4.52 to
56 5.23), $p < 0.0001$; deaths, 3.48% (95% CI, 3.18 to 3.81) vs 1.15% (95% CI, 1.00 to 1.34), $p < 0.0001$).

57 **Conclusion.** We report reduction in proportion of hospitalisations and deaths from SARS-CoV-2
58 infections during the Omicron variant dominated wave in Malawi, in the context of high SARS-CoV-2
59 seroprevalence but low COVID-19 vaccination coverage. These findings suggest that COVID-19
60 vaccination policy in high seroprevalence settings may need to be amended from mass campaigns to
61 targeted vaccination of at-risk populations.

62 Introduction

63 The B.1.1.529 (Omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was
64 first reported in South Africa on 25th November 2021. Within approximately 25 days the Omicron variant
65 was responsible for over 90% of the new clinical cases in South Africa, compared to 80% with the Delta
66 variant 100 days after its emergence in the same setting ¹. Compared to wild type SARS-CoV-2, the
67 Omicron infection rate was four times higher and the Delta rate was twice as high ². Genomic
68 sequencing of the Omicron variant has revealed a wide range of non-synonymous mutations ^{3,4}, with 30
69 mutations identified within its spike protein that have been linked to its high transmission rate and
70 greater immune evasion of neutralizing antibodies ⁵⁻⁷. Despite the Omicron variant being associated with
71 higher transmissibility, coronavirus disease (COVID-19) cases caused by this variant have mostly been
72 less severe than previous variants in both low middle income and high-income settings ^{1,8}.

73
74 The COVID-19 pandemic trajectory in Malawi has mirrored that of South Africa ⁸. Post emergence of
75 variants of concern in South Africa, Malawi has experienced three COVID-19 waves, caused by Beta,
76 Delta and Omicron ⁸. As of July 2022, the number of reported COVID-19 clinical cases and deaths in
77 Malawi were 86,823 and 2,651, respectively ⁹. However, in the context of a low COVID-19 vaccination
78 coverage (4.5%) in Malawi ⁹, data from a serosurvey among blood donors showed very high
79 seropositivity (>65%) by July 2021 ¹⁰, suggesting widespread community transmission and a huge under-
80 ascertainment of SARS-CoV-2 infections and possibly deaths. A recent sero-epidemiological study in
81 South Africa found high SARS-CoV-2 seropositivity in COVID-19 unvaccinated (68%) and vaccinated
82 (93%) individuals prior to the onset of the Omicron wave, and this was associated with reduced
83 incidence of COVID-19 hospitalisation, recorded deaths and excess deaths thereafter ¹. Consequentially,
84 South Africa has taken a more pragmatic approach to COVID-19, accepting the limited success in
85 preventing infections and allowing for policy development that is built on minimising severe COVID-19,
86 while balancing the direct and indirect societal effects of COVID-19 ^{11,12}. However, South Africa is the
87 richest economy on the continent ¹³, had stringent lockdowns and has epidemiological profiles of
88 communicable and non-communicable co-morbidities that differ from elsewhere in the region ^{11,12,14}. To
89 inform public health policy decisions in very low COVID-19 vaccine coverage and resource-constrained
90 countries such as Malawi, further data are urgently needed.

91
92 We, therefore, undertook a population-based serosurvey in Malawi that was conducted from December
93 27, 2022 to January 17, 2022, during the Omicron-dominant fourth wave. Furthermore, we link this data

94 to the national COVID-19 epidemiologic trends in Malawi, including clinical cases, hospitalizations and
95 deaths, from April 1, 2021 through April 30, 2022.

96

97 **Methods**

98 **Study design**

99 The study used a stratified multistage probability sample design, with strata defined by five health
100 zones, primary sampling units (PSU) defined by enumeration areas (EAs) within strata, second-stage
101 sampling units defined by households within EAs, and finally eligible persons within households.
102 Following a sample size calculation, the intention was to sample 12 of the 29 districts of Malawi but due
103 to logistical and operational challenges, only 7 of the 12 districts, namely Kasungu, Dowa, Dedza,
104 Lilongwe, Zomba, Machinga, and Blantyre, were included in the study participant recruitment phase
105 from 27th December 2021 to 17th January 2022. The 7 districts harbor 45% of the population of Malawi
106 (7,911,594 of 17,563,749 persons)¹⁵. The other 5 districts that constitute 13% of the Malawi's
107 population (2,221,932 of 17,563,749 persons)¹⁵ were included in an earlier serosurvey. The districts of
108 Lilongwe (2,626,901), Zomba (851,737) and Blantyre (1,251,484) have both rural and urban areas, and
109 harbor 3 of Malawi's main 4 cities.

110

111 **Sample size calculation**

112 We assumed 5% prevalence of SARS-CoV-2 antibodies, a margin of error of ±5 %, 95% precision of
113 estimates, and a design effect of 1.26. Using the following formula, we calculated a sample size (n) of
114 7,744 persons.

$$115 \quad n = \frac{DEFF \times Np(1-p)}{d^2 / Z_{1-\alpha/2}^2 \times (N-1) + p \times (1-p)}$$

116 Where;

117 Population size (N): 17,563,749

118 Hypothesized estimate of the prevalence of SARS-CoV-2 (p): 5%±5

119 Confidence limits as % of 100(absolute +/- %) (d): 5%

120 Design effect (DEFF): 1.26

121

122 Malawi has five health zones in three administrative regions (North, Southeast, Southwest, Central East,
123 and Central West). Districts were selected across Malawi using simple randomisation within the health
124 zones, choosing 2 districts per health zone, making a total of 10 districts, namely Nkhata Bay, Mzimba

125 North, Kasungu, Dowa, Ntcheu, Dedza, Zomba, Machinga, Nsanje, and Neno. Additionally, the two
126 largest cities of Blantyre and Lilongwe were added, totaling 12 districts. The PSUs were selected with
127 probabilities proportionate to the number of households in the EA based on the 2018 census¹⁵. The
128 second-stage sampling units were selected from lists of households compiled by trained staff for each of
129 the sampled PSUs. Upon completion of the listing process, a random systematic sample of households
130 was selected from each PSU within each health zone to the extent feasible. Within the sampled
131 households, all eligible participants were included in the study sample for data collection. Assuming an
132 average household size of 4.4 from the national census¹⁵, the estimated households to be recruited was
133 1,760. However, for the 7 districts, the expected number of households to be recruited was 1,420 and a
134 total sample size of 6,248 persons.

135
136 Inclusion criteria included being aged ≥ 5 years, residing in the sampled household, providing informed
137 written consent (or consent from parent/guardian and assent if aged 12 to 17 years), willing to provide
138 the required samples, and having no recent history of nose bleeding. After the consenting process, a
139 standard COVID-19 screening tool was implemented using electronic data capturing (Open Data Kit,
140 ODK), including demographic data, socio-economic status, comorbidities, COVID-19 symptoms, and
141 COVID-19 vaccination status from each enrolled individual. COVID-19 vaccination status was ascertained
142 from all participants using the individual national COVID-19 vaccination card.

143
144 The National Health Sciences Research Committee (NHSRC) (Protocol #21/02/2671) gave ethical
145 approval for this work and further authorization was also obtained from the District Health Offices of
146 the participating districts. Community sensitization within each district was implemented through
147 community leadership and study staff prior to data collection. All participants provided written informed
148 consent including assent for children; those who were approached were informed that they were free to
149 decline participation or withdraw at any time without any negative repercussion.

150

151 [Sample collection and processing](#)

152 Peripheral venous blood samples (4ml) were obtained from all enrolled participants. Samples were
153 transported to the district laboratory, where serum was separated by density centrifugation, aliquoted
154 and kept at 2-8°C for transportation to the main storage facility at the National Public Health Reference
155 Laboratory (NPHRL) repository. Serum was archived at -80°C.

156

157 Serological analysis

158 SARS-CoV-2 Receptor Binding Domain protein immunoglobulin were measured qualitatively in sera
159 using the WANTAI SARS-CoV-2 total antibody commercial ELISA kit as described previously ¹⁰, following
160 the manufacturer's instructions (Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., China; WS-
161 1096). The sensitivity and specificity of the assay as independently validated are 94% [95% *CI* 0.91 to
162 0.97]) and 100% [95% *CI* 0.99 to 1,00]), respectively ¹⁶. The results are expressed as a ratio which is
163 calculated by dividing the optical densities of the test sample by those of assay cutoff (mean OD of three
164 internal negative calibrators + 0.16). Specimens giving a ratio of < 0.9 were reported as negative for this
165 assay, a ratio of > 1.1 were reported as positive, and a ratio between 0.9 and 1.1 were reported as
166 borderline. Samples with borderline results were retested using a confirmatory assay described below.

168 National COVID-19 data sources

169 Data regarding daily cases, hospitalizations, and deaths were sourced from the Public Health Institute of
170 Malawi (PHIM), from 1st April 2021 through 30th April 2022 ⁹. In brief, the routine national COVID-19
171 reporting system works as follows: data from multiple sources at district level covering a 24-hour period
172 (6am-6am) are sent to national level through the national Public Health Emergency Operations Centre
173 (PHEOC). The data undergoes a triple verification system against three sources, surveillance, laboratory,
174 and case management, and then released to the public.

176 Cases included asymptomatic and symptomatic infections with SARS-CoV-2 confirmed by either a
177 nucleic acid amplification assay or a rapid antigen test. Hospitalizations included admissions for SARS-
178 CoV-2 infection, as well as admissions for other illnesses in which SARS-CoV-2 infection was incidentally
179 identified on routine screening at the time of admission. Death attributable to COVID-19 was defined as
180 a death resulting from a clinically compatible illness in a probable or confirmed COVID-19 case unless
181 there is a clear alternative cause of death that was not related to COVID-19 disease (e.g., trauma),
182 according to Malawi national guidelines.

184 Statistical methods

185 Statistical analyses were performed using R statistical package (version 4.1.0) ¹⁷. Categorical variables
186 were summarized as frequencies and percentages. Seropositivity was calculated as the proportion of
187 those who tested positive among all those tested. The overall seroprevalence of the SARS-CoV-2
188 antibodies was adjusted for both the assay's sensitivity (94% [95% *CI* 0.91 to 0.97]) and specificity (100%

189 [95% CI 0.99 to 1,00])¹⁶. The χ^2 test or Fisher's exact test was used to compute the proportions of
190 participants by number of COVID-19 vaccine doses received across several variables. A multivariate
191 logistic regression model was developed to investigate the factors associated with SARS-CoV-2
192 seropositivity. The factors included age, sex, occupational exposure and COVID-19 vaccination, which
193 were chosen based on known predictors of seropositivity. A p-value of <0.05 was considered
194 statistically significant.

195

196 **Results**

197 **Participant demographic and household characteristics**

198 We enrolled 4,639 participants from 1,415 households, with 4,619 samples from the participants
199 analysed (**Figure 1**). This constituted 74% of the target sample of 6,248 persons. The response rate was
200 generally high across all districts however reasons for refusal included cultural and religious beliefs
201 against drawing of blood, mistaking the serosurvey for COVID-19 vaccination programmes, lack of
202 incentive and general fear towards COVID-19 related activities. Demographic and household
203 characteristics, comorbidities, participant-reported HIV status, and COVID-19 vaccination status are
204 shown in **Table 1**. In brief, 60% (2,751/4,619) of the participants were between the ages of 18 to 50
205 years, 57% (2,617/4,619) were female, and 7.8% (361/4619) reportedly had had a chronic illness other
206 than HIV infection.

207

208 **SARS-CoV-2 seroprevalence estimates**

209 Among all participants, the overall assay sensitivity and specificity adjusted seroprevalence was 86.3%
210 (95% confidence interval (CI), 85.1% to 87.5%). The adjusted seroprevalence was heterogeneous across
211 the districts, ranging from 80.4% (95% CI, 75.9% to 84.6%) in Dowa, to 93.7% (95% CI, 91.1% to 96.0%) in
212 Blantyre (**Table 2**).

213

214 Participants residing in urban areas were more likely to test seropositive than those from rural areas
215 (91% vs. 78%; adjusted odds ratio, 2.81; 95% CI, 2.20 to 3.62) (**Table 3**). Males were less likely to be
216 seropositive than females (78% vs 84%; adjusted odds ratio, 0.61; 95% CI, 0.52 to 0.72). The
217 seroprevalence among the age groups did not vary greatly among those aged 13 years and above; but it
218 was lowest in children younger than 13 years of age (66%) and highest among adults 18 to 50 years of
219 age (82%). Children 13 to 17 years of age were more likely to be seropositive than children younger than
220 13 years of age (78% vs. 66%; adjusted odds ratio, 1.80; 95% CI, 1.15 to 2.83). Participants who had

221 received a COVID-19 vaccine were more likely to be seropositive than unvaccinated participants (1 dose
222 vs no dose, 94% vs. 77%; adjusted odds ratio, 4.83; 95% CI, 3.40 to 7.10; 2 doses vs no dose, 97% vs.
223 77%; adjusted odds ratio, 6.65; 95% CI, 4.16 to 11.4).

224

225 Participants who reported COVID-19 symptoms in the last two weeks, including persistent cough, loss of
226 taste, sore throat, chest pain, myalgia, shortness of breath, severe/unusual headache, fatigue, fever and
227 runny/blocked nose, were more likely to be seropositive than participants who did not report any
228 symptoms (83% vs. 80%; adjusted odds ratio, 1.21; 95% CI, 1.03 to 1.42) (**Table 3**). Participants who
229 reached secondary (86 % vs. 78 %; adjusted odds ratio, 1.27; 95% CI, 1.02 to 1.59) and tertiary (96 % vs.
230 78 %; adjusted odds ratio, 2.83; 95% CI, 1.49 to 5.99) education levels had a higher seroprevalence than
231 participants at primary education level. Participants with a regular waged job were more likely to be
232 seropositive than unwaged participants (93 % vs. 79 %; adjusted odds ratio, 1.60; 95% CI, 1.02 to 2.61).

233

234 COVID-19 vaccination

235 Of the 4,619 participants who were included in the data analysis, 3,794 of them had known age and
236 were eligible for COVID-19 vaccination at the time of the study being 18 years and older (**Table 4**).
237 Overall, 23% (878/3,794) of the participants had received at least one dose of the COVID-19 vaccine,
238 with 12% (458/3,794) receiving 1 dose and 11% (420/3,794) received 2 doses. The age group of 50 years
239 and above had a higher proportion of vaccinated individuals than those between 18 to 49 years (33% vs.
240 19%, $p < 0.001$). Moreover, the age group of 50 years and above had a higher proportion of vaccinated
241 individuals that received 2 doses than those between the ages of 18 to 49 years (19% vs. 8%).

242

243 All major cities of Lilongwe (16%), Blantyre (15%) and Zomba (13%), had a greater proportion of
244 individuals that received two doses of COVID-19 vaccine compared to the other districts (all $< 9.6\%$).
245 Moreover, the proportion of 2-dose vaccinated individuals was higher in urban areas than rural areas
246 (17% vs 14%, $p < 0.001$). A greater proportion of participants who had gone up to tertiary education level
247 (28%) received two doses of the COVID-19 vaccine, whereas those at primary and secondary level were
248 8% and 14%, respectively ($p < 0.001$). The proportion of 2-dose vaccinated people were higher ($p < 0.001$)
249 among those with a regular wage (35%) compared to unwaged (9%) or those with an irregular wage
250 (11%).

251

252 National COVID-19 epidemiological trends

253 Our study was conducted during the fourth wave, which was dominated by the Omicron variant ^{18,19}.
254 During this wave, the daily case incidence increased more rapidly and also decreased more quickly
255 compared to the third (Delta) wave, with the peak in July 2021 and December 2021, respectively (**Figure**
256 **2**). The number of confirmed clinical cases at the peak of the third wave were 13300 and during the
257 fourth wave were 14298, whereas the peak episodes of hospitalization were 1429 and 695, while deaths
258 were 463 and 164, respectively. The proportion of hospitalisation within the confirmed clinical cases was
259 two-fold lower in the fourth wave compared to the third wave (4.86% (95% CI, 4.52 to 5.23) (695/14298)
260 vs 10.7% (95% CI, 10.2 to 11.3) (1429/13330), $p < 0.0001$). While, the proportion of deaths within the
261 confirmed clinical cases was three-fold lower in the fourth wave compared to the third wave (1.15%
262 (95% CI, 1.00 to 1.34) (164/14298) vs 3.48% (95% CI, 3.18 to 3.81) (463/13330), $p < 0.0001$).

263

264 Discussion

265 The results of our study showed high SARS-CoV-2 seropositivity of 86% across the population during the
266 Omicron B.1.1.529 variant-dominated fourth wave. This high seroprevalence was primarily due to prior
267 SARS-CoV-2 infection, as evidence by the low vaccine uptake in this population and the 70%
268 seroprevalence among participants who had not received a COVID-19 vaccine. Against this background,
269 we observed reduction in the proportion of hospitalization and deaths from the reported infections
270 during the Omicron-dominated fourth wave, compared to the Delta-dominated third wave. This is in
271 support of Madhi *et al* that have observed a similar phenomenon in South Africa, which they termed
272 “decoupling” ²⁰.

273

274 Notwithstanding the reduced number of hospitalization and deaths in Malawi, the Omicron variant
275 drove a rapid rise in SARS-CoV-2 infections consistent with its high transmissibility ^{21,22} as observed in
276 other settings ^{1,23}. Based on previous estimates from our adult blood donor serosurvey, the estimated
277 seroprevalence by July 2021 was $>65\%$ ¹⁰, reaching around 80% by November 2021 (unpublished),
278 before the Omicron-dominant fourth wave in Malawi. In South Africa, a lower rate of hospitalization and
279 deaths was associated with the high seroprevalence before the onset of the Omicron-dominant wave,
280 driven by both vaccination and infection ¹. In Malawi, there was at least a two-fold reduction in
281 proportion of COVID-19 hospitalizations and deaths among the clinical cases reported in the fourth
282 compared to third wave. Madhi *et al.* suggests that, in South Africa, cell-mediated immunity induced
283 through prior infection and vaccination contributed to protective immunity against severe disease ¹. This

284 suggestion was based on earlier evidence that showed that the Omicron variant highly evades
285 neutralization antibody activity^{5-7,24} but is ably cross-recognized by T cells^{25,26}. Evidence of T cell-
286 mediated protection against COVID-19 is accumulating and is consistent with their role in viral
287 clearance, where they might not directly prevent infection but halt progression of infection to disease
288 ^{27,28}.

289
290 The SARS-CoV-2 seroprevalence was generally high across all the seven districts surveyed in the current
291 study, with higher seroprevalence in urban compared to rural areas, as reported in our blood donor
292 serosurvey¹⁰ and in other sub-Saharan African settings²⁹. This is consistent with national COVID-19 data
293 at the time of the study that reported 51% of confirmed cases in the country were from the cities of
294 Blantyre and Lilongwe⁹, with a caveat that rural areas had relatively fewer SARS-CoV-2 testing sites. The
295 high seroprevalence seen in the urban areas could be attributed to these areas being hotspots for SARS-
296 CoV-2 transmission. Individuals residing in the urban areas were more likely to have attained higher
297 level education and have regular waged jobs, likely increasing their risk of exposure due to increased
298 interaction with others, closed workspaces, frequent travel on public transport and international travel
299 that also increases the risk of exposure to new variants. Supporting this, seroprevalence was higher in
300 those with secondary or tertiary level education, and in those on regular waged jobs. Our study also
301 found men to have a lower seropositivity, which is contrary to male-dominated reported national
302 COVID-19 cases, this could suggest that females experienced less severe forms of COVID-19 to trigger
303 testing or were less likely to present for testing. These findings highlight the need to tailor public health
304 measures according to context as the pandemic progresses.

305
306 Our study has some limitations. First, we used an anti-RBD ELISA assay that was developed against the
307 wild type SARS-CoV-2, hence the extensive mutations in the RBD in the Omicron variant could result in
308 false negative results in individuals who were previously or actively infected with this variant.
309 Nevertheless, considering the extremely high seroprevalence, our conclusions are unlikely to be
310 significantly impacted by the theoretical possibility of lower assay specificity. Second, the use of publicly
311 available reported national COVID-19 surveillance data has its own caveats, including under
312 ascertainment of the cases and deaths or changes in testing strategies over time, and this needs to be
313 taken into consideration when interpreting the comparisons across the waves. However, to our
314 knowledge, there were no significant changes in the clinical management policy of severe COVID-19
315 cases between the third and fourth waves, hence the comparison between the waves is likely accurate.

316 Thirdly, we had a relatively small numbers of children to give precise estimates of seroprevalence in this
317 population. Finally, the study was conducted and concluded before the end of the fourth wave, hence
318 this could result in seroprevalence estimates being an underestimate of the actual cumulative exposure
319 for Malawi.

320
321 The reduction in the proportion of hospitalizations and deaths from COVID-19 during the Omicron-
322 dominant fourth wave in Malawi, in the context of low vaccination coverage and high infection-induced
323 seroprevalence, could be a watershed moment for the COVID-19 pandemic in under-vaccinated
324 countries like Malawi. However, the number of COVID-19 preventable deaths are still significant and a
325 greater focus on identifying and protecting those most at risk is increasingly important. Up until a
326 sarbecoviruses or pan-coronavirus vaccine is available, to maximise protection against severe disease in
327 high seroprevalence and resource-constrained settings like Malawi, there might be the need to amend
328 vaccination policy of current COVID-19 vaccines from mass vaccination campaigns to targeted
329 vaccination that focuses on at-risk populations including the elderly and those with co-morbidities.

330

331 **Acknowledgements**

332 The authors thank all participants whose samples are used in this study. We thank all the district teams
333 and leadership for their support and contribution to this study. We also thank Mtisunge Yelewa,
334 Selemani Ngwira, Eranive Chipungu, Triza Chirwa, and Sikhona Chipeta. We acknowledge use of the
335 WHO Unity protocols for this study.

336

337 **Author contributions**

338 Conceptualization of study: ACM, WK, OD, DK, JP, CM

339 Study design: ACM, WK, OD, DK, JP, CM, MK, ND

340 Data collection: ULM, DM, KN

341 Laboratory testing: JM, MM, IC, BO

342 Data analysis: KCJ1, ULM, JM

343 Accessed and verified the underlying data: KCJ1, MK

344 Study management: ULM, KN

345 Initial manuscript draft: ULM, KCJ1, ACM

346 Final manuscript writing: ULM, KCJ1, ACM, RSH, TDS, KCJ2, NF, ASA, AC

347 Manuscript review and approval: All authors

348 **Funding**

349 Supported by the Bill and Melinda Gates Foundation (INV-039481).

350

351 **Declaration of interest**

352 All authors declare no conflict of interest.

353

354 **References**

- 355 1. Madhi SA, Kwatra G, Myers JE, et al. Population Immunity and Covid-19 Severity with Omicron
356 Variant in South Africa. *N Engl J Med* 2022; **386**(14): 1314-26.
- 357 2. Araf Y, Akter F, Tang Y-d, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and
358 responses to current COVID-19 vaccines. *Journal of Medical Virology* 2022; **94**(5): 1825-32.
- 359 3. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant
360 in southern Africa. *Nature* 2022; **603**(7902): 679-86.
- 361 4. McCallum M, Czudnochowski N, Rosen LE, et al. Structural basis of SARS-CoV-2 Omicron immune
362 evasion and receptor engagement. *Science* 2022; **375**(6583): 864-8.
- 363 5. Hu J, Peng P, Cao X, et al. Increased immune escape of the new SARS-CoV-2 variant of concern
364 Omicron. *Cellular & Molecular Immunology* 2022; **19**(2): 293-5.
- 365 6. Mannar D, Saville JW, Zhu X, et al. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM
366 structure of spike protein–ACE2 complex. *Science* 2022; **375**(6582): 760-4.
- 367 7. Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-
368 mediated neutralization: Implications for control of the COVID-19 pandemic. *Cell* 2022; **185**(3): 447-
369 56.e11.
- 370 8. JHU. COVID-19 Case Tracker 2020. <https://coronavirus.jhu.edu/map.html>.
- 371 9. PHIM. Daily COVID-19 Situation Report. Lilongwe: Public Health Institute of Malawi, Ministry of
372 Health 2022.
- 373 10. Mandolo J, Msefula J, Henrion MYR, et al. SARS-CoV-2 exposure in Malawian blood donors: an
374 analysis of seroprevalence and variant dynamics between January 2020 and July 2021. *BMC Med* 2021;
375 **19**(1): 303.
- 376 11. Madhi S, Abdullah F, Myers J. South Africa has changed tack on tackling COVID: why it makes
377 sense. *The Conversation*. 2022.
- 378 12. Ueckermann V. What South Africa has learnt about COVID and what the next steps could be. *The*
379 *Conversation*. 2022 15 February 2022.
- 380 13. Bank TW. GDP per capita. 2022. <https://data.worldbank.org>.
- 381 14. WHO. Monitoring health for the SDGs, sustainable development goals: WHO, 2022.
- 382 15. NSO. Malawi Population and Housing Census. Zomba: National Statistical Office, Malawi, 2018.
- 383 16. Wantai. WANTAI SARS-CoV-2 Ab ELISA 2021. <https://www.fda.gov/media/140929/download>.
- 384 17. Team RC. R: A language and environment for statistical computing. . 2021. [https://www.R-](https://www.R-project.org/)
385 [project.org/](https://www.R-project.org/).
- 386 18. Anscombe C, Lissauer S, Thole H, et al. A comparison of four epidemic waves of COVID-19 in
387 Malawi; an observational cohort study. *medRxiv* 2022: 2022.02.17.22269742.
- 388 19. Chibwana MG, Thole HW, Anscombe C, et al. Differential symptoms among COVID-19 outpatients
389 before and during periods of SARS-CoV-2 Omicron variant dominance in Blantyre, Malawi: a prospective
390 observational study. *medRxiv* 2022: 2022.07.15.22277665.

- 391 20. Madhi SA, Ihekweazu C, Rees H, Pollard AJ. Decoupling of omicron variant infections and severe
392 COVID-19. *Lancet* 2022; **399**(10329): 1047-8.
- 393 21. Willett BJ, Grove J, MacLean OA, et al. The hyper-transmissible SARS-CoV-2 Omicron variant
394 exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism. *medRxiv* 2022:
395 2022.01.03.21268111.
- 396 22. Peacock TP, Brown JC, Zhou J, et al. The SARS-CoV-2 variant, Omicron, shows rapid replication in
397 human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. *bioRxiv* 2022:
398 2021.12.31.474653.
- 399 23. Elliott P, Bodinier B, Eales O, et al. Rapid increase in Omicron infections in England during
400 December 2021: REACT-1 study. *Science* 2022; **375**(6587): 1406-11.
- 401 24. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing
402 antibodies. *Nature* 2022; **602**(7898): 657-63.
- 403 25. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize
404 Omicron. *Nature* 2022.
- 405 26. Naranbhai V, Nathan A, Kaseke C, et al. T cell reactivity to the SARS-CoV-2 Omicron variant is
406 preserved in most but not all individuals. *Cell* 2022; **185**(6): 1041-51.e6.
- 407 27. Moss P. The T cell immune response against SARS-CoV-2. *Nature Immunology* 2022; **23**(2): 186-
408 93.
- 409 28. Bange EM, Han NA, Wileyto P, et al. CD8(+) T cells contribute to survival in patients with COVID-
410 19 and hematologic cancer. *Nat Med* 2021; **27**(7): 1280-9.
- 411 29. Kleynhans J, Tempia S, Wolter N, et al. SARS-CoV-2 Seroprevalence in a Rural and Urban
412 Household Cohort during First and Second Waves of Infections, South Africa, July 2020-March 2021.
413 *Emerg Infect Dis* 2021; **27**(12): 3020-9.

414

415

416

417

418

419

420

421

422

423

424

425

426 **Figure legends**

427 **Figure 1. Survey participant recruitment.** The survey was conducted between 27th December 2021 to
428 17th January 2022. The survey included primary sampling units (PSU), which were selected with
429 probabilities proportionate to the number of households based on the 2018 census. The second-stage
430 sampling units were selected from lists of households sampled PSUs, then a random systematic sample
431 of households was selected from each PSU within each health zone to the extent feasible.

432

433 **Figure 2. COVID-19 Cases, Hospitalizations, and Deaths in Malawi, from April 2021 through April 2022.**
434 Shown are incidences of monthly cases, hospitalizations, and deaths attributable to coronavirus disease
435 2019 (COVID-19). The data were sourced from the Public Health Institute of Malawi (PHIM). Cases
436 included asymptomatic and symptomatic infections with severe acute respiratory syndrome coronavirus
437 2 (SARS-CoV-2) confirmed by either a nucleic acid amplification assay or a rapid antigen test.
438 Hospitalizations included admissions for SARS-CoV-2 infection, as well as admissions for other illnesses
439 in which SARS-CoV-2 infection was incidentally identified on routine screening at the time of admission.
440 Death attributable to COVID-19 was defined as a death resulting from a clinically compatible illness in a
441 probable or confirmed COVID-19 case unless there is a clear alternative cause of death that cannot be
442 related to COVID disease (e.g., trauma), according to the national guidelines

443

444

445

446

447

448

449

450

451

452 **Tables**

453 **Table 1. Participant demographics and clinical history**

Characteristic	N = 4,619 [†]
Sex	
Female	2,617 (57%)
Male	2,002 (43%)
Age group	
<13 yrs	187 (4.4%)
13 to 17 yrs	230 (5.5%)
18 to 50 yrs	2,751 (65%)
>50 yrs	1,043 (25%)
Unknown	408
COVID-19 Vaccination status	
0 doses	3,606 (78%)
1 dose	521 (11%)
2 doses	492 (11%)
SARS-CoV-2 serostatus	
Negative	865 (19%)
Positive	3,754 (81%)
Symptoms in the last 2 weeks	
Yes	1,747 (38%)
No	2,870 (62%)
Unknown	2 (<0.1%)
Occupation	
Irregular	522 (11%)
Regular	364 (7.9%)
Unwaged	3,733 (81%)
Education level	
Primary	2,086 (45%)
Secondary	1,038 (22%)
Tertiary	232 (5.0%)
No formal education	1,263 (27%)
Comorbidities	
Yes	361 (7.8%)
No	4,258 (92%)
HIV status	
HIV-	4,457 (96%)
HIV+	162 (3.5%)
Economic zone	
Urban	1,373 (30%)
Rural	1,156 (25%)
*Other	2,090 (45%)
Location	
Blantyre	768 (17%)
Dedza	527 (11%)
Dowa	441 (9.5%)
Kasungu	645 (14%)
Lilongwe	1,327 (29%)
Machinga	477 (10%)
Zomba	434 (9.4%)
[†] n (%)	

454

455 * includes other districts apart from city-harboring districts of Lilongwe, Blantyre and Zomba

456

457 **Table 2. SARS-CoV-2 antibody seroprevalence estimates**

	<i>n</i>	<i>Seroprevalence</i>	<i>95% Confidence Interval</i>	<i>Seroprevalence *(adjusted)</i>	<i>95% Confidence Interval *(adjusted)</i>
<i>All</i>	3755/4619	81.3%	80.1% to 82.4%	86.5%	83.3% to 89.2%
<i>>13 years</i>	124/188	66.3%	59.1% to 73.0%	70.2%	62.0% to 77.5%
<i>13-17 years</i>	179/230	77.8%	71.9% to 83.0%	82.8%	75.8% to 88.8%
<i>18-50 years</i>	2261/2750	82.2%	80.7% to 83.6%	87.5%	84.1% to 90.5%
<i>>50 years</i>	847/1043	81.2%	78.7% to 83.5%	86.4%	82.3% to 89.9%
<i>Blantyre</i>	678/768	88.3%	85.8% to 90.5%	93.9%	89.7% to 97.5%
<i>Dedza</i>	406/527	77.0%	73.2% to 80.6%	81.9%	76.9% to 86.3%
<i>Dowa</i>	334/441	75.7%	75.7% to 79.7%	80.6%	75.1% to 85.2%
<i>Kasungu</i>	486/645	75.3%	71.8% to 78.6%	80.2%	75.4% to 84.3%
<i>Lilongwe</i>	1132/1327	85.3%	83.3% to 87.2%	90.8%	86.9% to 94.0%
<i>Machinga</i>	380/477	79.7%	75.8% to 83.2%	84.8%	79.6% to 89.2%
<i>Zomba</i>	338/434	77.9%	73.7% to 81.7%	82.9%	77.4% to 87.5%
<i>Urban</i>	1252/1373	91.2%	89.6% to 92.6%	97.0%	93.6% to 99.6%
<i>Rural</i>	896/1156	77.5%	75.0% to 79.9%	82.5%	78.5% to 85.9%

458 * The sensitivity and specificity of the assay as independently validated are 94% [95% *CI* 0.91 to 0.97])
 459 and 100% [95% *CI* 0.99 to 1.00]), respectively

460

461

462

463

464

465

466

467

468

469

470

471

472

473 **Table 3. Factors associated with SARS-CoV-2 antibody seropositivity**

Characteristic	Seropositivity				Univariate			Multivariable			
	Overall, N = 4,619 ¹	Negative, N = 865 ¹	Positive, N = 3,754 ¹	p-value ²	N	OR ³	95% CI ³	p-value	OR ³	95% CI ³	p-value
Age group				<0.001	4,619						
<13 yrs	187 (100%)	63 (34%)	124 (66%)			—	—		—	—	
13 to 17 yrs	230 (100%)	51 (22%)	179 (78%)			1.78	1.16, 2.76	0.009	1.76	1.13, 2.77	0.013
18 to 50 yrs	2,751 (100%)	490 (18%)	2,261 (82%)			2.34	1.70, 3.21	<0.001	1.68	1.19, 2.35	0.003
>50 yrs	1,043 (100%)	196 (19%)	847 (81%)			2.20	1.56, 3.08	<0.001	1.56	1.08, 2.24	0.017
Unknown						2.68	1.79, 4.02	<0.001	1.82	1.18, 2.80	0.006
Sex				<0.001	4,619						
Female	2,617 (100%)	417 (16%)	2,200 (84%)			—	—		—	—	
Male	2,002 (100%)	448 (22%)	1,554 (78%)			0.66	0.57, 0.76	<0.001	0.61	0.52, 0.72	<0.001
Economic zone				<0.001	4,619						
Rural	1,156 (100%)	260 (22%)	896 (78%)			—	—		—	—	
Urban	1,373 (100%)	121 (8.8%)	1,252 (91%)			3.00	2.39, 3.80	<0.001	2.81	2.20, 3.62	<0.001
*Other	2,090 (100%)	484 (23%)	1,606 (77%)			0.96	0.81, 1.14	0.7	1.00	0.84, 1.20	>0.9
Education level				<0.001	4,619						
Primary	2,086 (100%)	463 (22%)	1,623 (78%)			—	—		—	—	
Secondary	1,038 (100%)	146 (14%)	892 (86%)			1.74	1.43, 2.14	<0.001	1.28	1.02, 1.60	0.032
Tertiary	232 (100%)	10 (4.3%)	222 (96%)			6.33	3.52, 12.9	<0.001	2.84	1.49, 6.00	0.003
No formal education	1,263 (100%)	246 (19%)	1,017 (81%)			1.18	0.99, 1.40	0.062	0.97	0.81, 1.18	0.8
Occupation				<0.001	4,619						
Unwaged	3,733 (100%)	768 (21%)	2,965 (79%)			—	—		—	—	
Irregular	522 (100%)	73 (14%)	449 (86%)			1.59	1.24, 2.08	<0.001	1.14	0.87, 1.52	0.4
Regular	364 (100%)	24 (6.6%)	340 (93%)			3.67	2.46, 5.74	<0.001	1.60	1.02, 2.60	0.051
Any symptoms in the last 2 weeks				0.079	4,619						
Yes	1,747 (100%)	304 (17%)	1,443 (83%)			—	—		—	—	
No	2,870 (100%)	560 (20%)	2,310 (80%)			0.87	0.74, 1.01	0.075	0.83	0.70, 0.97	0.024
Unknown	2 (100%)	1 (50%)	1 (50%)			0.21	0.01, 5.34	0.3	0.05	0.00, 1.76	0.071
COVID-19 Vaccination status				<0.001	4,619						
0 doses	3,606 (100%)	816 (23%)	2,790 (77%)			—	—		—	—	
1 dose	521 (100%)	32 (6.1%)	489 (94%)			4.47	3.15, 6.57	<0.001	4.96	3.48, 7.33	<0.001
2 doses	492 (100%)	17 (3.5%)	475 (97%)			8.17	5.17, 13.9	<0.001	6.64	4.16, 11.4	<0.001

¹ n (%)
² Pearson's Chi-squared test; Fisher's exact test
³ OR = Odds Ratio, CI = Confidence Interval

474

475

476

477

478 **Table 4. COVID-19 vaccination**


479	Characteristic	Overall, N = 3,794¹	0 doses, N = 2,916¹	1 dose, N = 458¹	2 doses, N = 420¹	p-value²
480	Age group					<0.001
	18 to 50 yrs	2,751 (100%)	2,216 (81%)	312 (11%)	223 (8.1%)	
481	>50 yrs	1,043 (100%)	700 (67%)	146 (14%)	197 (19%)	
482	Sex					0.011
	Female	2,176 (100%)	1,689 (78%)	274 (13%)	213 (9.8%)	
	Male	1,618 (100%)	1,227 (76%)	184 (11%)	207 (13%)	
483	HIV status					0.6
	HIV-	3,668 (100%)	2,824 (77%)	441 (12%)	403 (11%)	
484	HIV+	126 (100%)	92 (73%)	17 (13%)	17 (13%)	
485	Location					<0.001
	Blantyre	611 (100%)	476 (78%)	44 (7.2%)	91 (15%)	
486	Dedza	468 (100%)	394 (84%)	61 (13%)	13 (2.8%)	
	Dowa	308 (100%)	208 (68%)	83 (27%)	17 (5.5%)	
487	Kasungu	538 (100%)	382 (71%)	105 (20%)	51 (9.5%)	
	Lilongwe	1,124 (100%)	834 (74%)	109 (9.7%)	181 (16%)	
488	Machinga	401 (100%)	364 (91%)	14 (3.5%)	23 (5.7%)	
	Zomba	344 (100%)	258 (75%)	42 (12%)	44 (13%)	
489	Education level					<0.001
	Primary	1,602 (100%)	1,265 (79%)	202 (13%)	135 (8.4%)	
490	Secondary	910 (100%)	685 (75%)	95 (10%)	130 (14%)	
	Tertiary	206 (100%)	128 (62%)	20 (9.7%)	58 (28%)	
491	No formal education	1,076 (100%)	838 (78%)	141 (13%)	97 (9.0%)	
492	Occupation					<0.001
	Irregular	462 (100%)	368 (80%)	45 (9.7%)	49 (11%)	
493	Regular	308 (100%)	169 (55%)	31 (10%)	108 (35%)	
	Unwaged	3,024 (100%)	2,379 (79%)	382 (13%)	263 (8.7%)	
494	Economic zone					<0.001
	Urban	1,123 (100%)	855 (76%)	82 (7.3%)	186 (17%)	
495	Rural	956 (100%)	713 (75%)	113 (12%)	130 (14%)	
496	*Other	1,715 (100%)	1,348 (79%)	263 (15%)	104 (6.1%)	
	¹ n (%)					
	² Pearson's Chi-squared test					

497 * includes other districts apart from city-harboring districts of Lilongwe, Blantyre and Zomba


498

499

500 **Figures**
501 **Figure 1.**



523 **Figure 2.**



524

525

526

527